NovaBay Pharmaceuticals, Inc. (NBY) stock is up 25.89% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Recent trends are a good indator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With NBY Stock Today?
NovaBay Pharmaceuticals, Inc. (NBY) stock is trading at $1.41 as of 2:25 PM on Tuesday, Aug 4, a gain of $0.09, or 6.82% from the previous closing price of $1.32. The stock has traded between $1.33 and $1.44 so far today. Volume today is less active than usual. So far 2,749,508 shares have traded compared to average volume of 8,045,477 shares.
To see InvestorsObserver's Sentiment Score for NovaBay Pharmaceuticals, Inc. click here.
More About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops, manufactures, and markets anti-infective products for a multitude of uses. It is predominantly focused on commercializing prescription Avenova for the domestic eye care market in the United States. Avenova is the only eye care product formulated with proprietary, stable and pure form of hypochlorous acid (marketed as Neutrox). The company develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. It has partnerships for NeutroPhase in the United States, as well as in other markets.
